These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 33054319)

  • 1. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
    Di Martino E; Provenzani A; Vitulo P; Polidori P
    Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
    Kou M; Jiao Y; Li Z; Wei B; Li Y; Cai Y; Wei W
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1445-1460. PubMed ID: 38963453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.
    Wu X; Li W; Luo Z; Chen Y
    BMC Pulm Med; 2024 Jan; 24(1):58. PubMed ID: 38281037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
    Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
    Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
    Raghu G; Richeldi L; Fernández Pérez ER; De Salvo MC; Silva RS; Song JW; Ogura T; Xu ZJ; Belloli EA; Zhang X; Seid LL; Poole L;
    JAMA; 2024 Aug; 332(5):380-389. PubMed ID: 38762797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
    Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
    Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.
    Skandamis A; Kani C; Markantonis SL; Souliotis K
    J Drug Assess; 2019; 8(1):55-61. PubMed ID: 31044096
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
    Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
    Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis.
    Sgalla G; Franciosa C; Simonetti J; Richeldi L
    Expert Opin Investig Drugs; 2020 Aug; 29(8):771-777. PubMed ID: 32447983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
    Ren H; Wang K; Yang H; Gao L
    Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
    Richeldi L; Fernández Pérez ER; Costabel U; Albera C; Lederer DJ; Flaherty KR; Ettinger N; Perez R; Scholand MB; Goldin J; Peony Yu KH; Neff T; Porter S; Zhong M; Gorina E; Kouchakji E; Raghu G
    Lancet Respir Med; 2020 Jan; 8(1):25-33. PubMed ID: 31575509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.